Loading...
•
Sep 30, 2024
Tyra Biosciences Q3 2024 Earnings Report
Reported positive interim clinical proof-of-concept results for TYRA-300, cleared IND for Phase 2 study of TYRA-300 in pediatric achondroplasia, strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer and held cash, cash equivalents, and marketable securities of $360.1 million.
Key Takeaways
Tyra Biosciences reported its Q3 2024 financial results, featuring positive interim data for TYRA-300 in mUC, progress in expanding TYRA-300 development into NMIBC, clearance for a Phase 2 achondroplasia study, and the appointment of Doug Warner as CMO. The company's cash reserves are expected to last through at least 2026.
Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study
IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301)
Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer
Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024
Forward Guidance
TYRA is focused on advancing its clinical programs and expects to dose the first child with achondroplasia in BEACH301 in Q1 2025 and submitting an IND for NMIBC by the end of this year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...